BSX, Boston Scientific Corporation
PWRM, Power 3 Medical Products Inc, PWRM.OB
DrStockPick Watch List!
DrStockPick Watch List! for Tuesday July 21, 2009 are:
My Picks for Tuesday July 21, 2009 are:
BSX, Boston Scientific Corporation
BSX operates as a developer, manufacturer, and marketer of medical devices used in various interventional medical specialties worldwide.
BSX�s products help physicians and other medical professionals improve the patients quality of life by providing alternatives to surgery.
To consider about BSX
Today, after Closing Bell, BSX announced financial results for the second quarter ended June 30, 2009.
Net sales for the second quarter of 2009 were $2.074 billion, as compared to net sales of $2.024 billion for the second quarter of 2008, which included sales from divested businesses of $19 million. Excluding the impact of foreign currency and sales from divested businesses, net sales increased seven percent over the prior period.
More about BSX at www.bostonscientific.com
PWRM, Power 3 Medical Products Inc, PWRM.OB
PWRM is a breakthrough proteomics company specializing in the identification of disease footprints in the areas of chemotherapeutic drug resistance and the early detection of breast cancer and neurological diseases.
The research platform is centered on the study of proteomics, the science of protein interactions within living cells. With a combined 50+ years of proteomic experience, PWRM has identified 334 protein biomarkers with the following potential medical applications:
+Breast Cancer +Chemotherapeutic Drug Resistance
+Alzheimer�s Disease +Leukemia
+ALS (Lou Gehrig�s Disease) +Gastrointestinal Disease
+Parkinson�s Disease +Metabolic Syndrome
�In the US, there are an estimated 5.1 million individuals with Alzheimer�s disease,� said Power3�s President and Chief Scientific Officer, Dr. Ira L. Goldknopf. �The annual treatment per patient is currently in excess of $30 thousand for Alzheimer�s.� �Unfortunately, this disease is often misdiagnosed, and may take up to 10 years before the correct diagnosis is rendered. By the time patients are given a probable diagnosis, they have already suffered substantial and irreparable brain damage, rendering treatment less effective, even with existing drugs�.
PWRM is conducting the independent validation of both their Alzheimer�s (NuroPro AD) and Parkinson�s (NuroPro PD) tests with key clinical centers.
�The progress of the clinical validation achieved to date affirms our belief that NuroPro PD will help physicians make earlier diagnoses and recommend appropriate follow-up and treatment options for their patients,� commented Helen R. Park, CEO of PWRM.
PWRM�s President and Chief Scientific Officer, Dr. Ira L. Goldknopf, presented a poster entitled �Differential Diagnosis of Neurodegenerative Diseases, Using Serum, a New Paradigm�, at the 12th International Conference of Neurodegenerative Disease in Vienna on July, 14, 2009.
More about PWRM at www.power3medical.com
Add BSX and PWRM to your Watch List!, do your homework, and like always BE READY for the ACTION!
No comments:
Post a Comment